For millions of Americans and especially the brave warfighters who bear the invisible wounds of conflict, traditional medicine has long fallen short. For decades, veterans and others suffering from post-traumatic stress disorder, traumatic brain injury, and severe substance use disorders have faced a system that moves too slowly. Too many families have watched loved ones struggle through treatments that too often fail to bring relief. This cycle of frustration has left many of our nation’s heroes with limited options and dwindling hope.
Today, that paradigm is changing. Under the Trump administration, a major shift is underway to ensure our warfighters receive the cutting-edge, lifesaving care they deserve.
The Food and Drug Administration has announced a Request for Information seeking public and expert input to its consideration of the design and conduct of early-stage clinical trials for ibogaine drug products. This action represents a major step forward in the development of these products. More importantly, it stands as a decisive victory for veterans and a clear testament to an administration committed to helping patients and researchers navigate complex study approaches in the relentless pursuit of medical innovation.
For years, veterans and their families have often felt forced to seek help outside our borders. Many have traveled internationally at immense personal expense to access unproven ibogaine therapies. Instead of shutting the door on complex compounds or leaving vulnerable patients to navigate foreign medical systems alone, the Trump administration is stepping in. The FDA today is bringing rigorous science, comprehensive safety oversight, and genuine hope back to American soil.
Ibogaine along with its metabolites and synthetic derivatives has demonstrated substantial promise in addressing conditions that are difficult to treat. Studies and anecdotal evidence suggest potential benefits for severe PTSD, traumatic brain injury, and opioid addiction. Nevertheless, ibogaine is a powerful compound with significant risks, particularly regarding cardiac and neurological function. Simply opening the floodgates without proper guidelines would be dangerous and irresponsible.
The FDA’s proactive measure opens a structured, evidence-based pathway for the development of clinical trials to investigate promising ibogaine treatments. It brings top experts, clinicians, researchers, and veteran advocates together to answer critical safety questions. By leveraging expert collaboration, the agency is actively seeking insight and information on, among other things, precise dosing protocols, strict cardiac monitoring standards, and identification of which patient populations stand to benefit the most, under ethical supervision.
This initiative reflects the core promise of the Trump administration to deliver innovative treatments as quickly and safely as possible to those who need them most. It does not exist in a vacuum. Rather, it builds on a series of decisive executive actions aimed at modernizing American healthcare and accelerating breakthroughs for serious mental illness.
These efforts build on President Donald Trump’s April 18 executive order, “Accelerating Medical Treatments for Serious Mental Illness,” which directed federal agencies to speed access to promising therapies. Within days the FDA awarded national priority vouchers to psychedelic therapies for depression and PTSD, cleared the first ever U.S. clinical study of an ibogaine derivative, noribogaine, and moved to finalize guidance for sponsors developing these treatments. By showing decisive leadership, we are creating a clear road map for safe and effective therapies.
I’M A DISABLED AIR FORCE VET. HERE’S WHY I’M GLAD I NEVER JOINED THE VFW
Rigorous science and compassionate access do not have to be mutually exclusive. By tackling safety concerns directly and working to establish an efficient regulatory roadmap, the FDA and the Trump administration are demonstrating what meaningful leadership in healthcare looks like. Our warfighters put everything on the line to defend our country and deserve a medical system that works just as hard to heal their wounds.
To our veterans, their families, and the countless number of people fighting severe mental health challenges, our message is simple. The Trump administration will not stand by and force you to suffer any longer. We will fulfill our duty to our heroes by bringing innovative treatments to the public, as quickly and safely as possible.
Kyle Diamantas is the acting commissioner of the Food and Drug Administration. Mike Davis is the director of the FDA’s Center for Drug Evaluation and Research.